NCT01320553View on ClinicalTrials.gov

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2011

Conditions
Allergic Conjunctivitis
Interventions
DRUG

SPARC1102 I

SPARC1102 I will be administered in both eyes

DRUG

SPARC1102 II

SPARC1102 II will be administered in both eyes

DRUG

SPARC1102 III

SPARC1102 III will be administered in both eyes

DRUG

Vehicle

Vehicle will be administered in both eyes

Trial Locations (1)

01810

ORA Inc, Andover

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT01320553 - Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter